Literatur
- 1
Anonymus.
Newer approaches to HIV prevention.
Lancet.
2007;
369
615
- 2
Bailey R C, Moses S, Parker C B. et al .
Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled
trial.
Lancet.
2007;
369
643-656
- 3
Blumenthal R, Dimitrov D S.
Targeting the Sticky Fingers of HIV-1.
Cell.
2007;
129
243-345
- 4
Brooks J T, Ochieng J B, Kumar L. et al .
Surveillance for bacterial diarrhea and antimicrobial resistance in rural western
Kenya, 1997 - 2003.
Clin Infect Dis.
2006;
43
393-401)
- 5
CDC.
Pertussis-United States, 2001 - 2003.
MMWR Morb Mortal Wkly Rep.
2005;
54
1283-1286
- 6
Chen A Y, Zervos M J, Vazquez J A.
Dalbavancin: a novel antimicrobial.
Int J Clin Pract.
2007;
61
853-863
- 7
Chretien J P, Anyamba A, Bedno S A. et al .
Drought-associated chikungunya emergence along coastal East Africa.
Am J Trop Med Hyg.
2007;
76
405-407
- 8
Clotet B, Bellos N, Molina J M. et al .
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients
with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two
randomised trials.
Lancet.
2007;
369
1169-1178
- 9
Dewan P K, Grinsdale J, Kawamura L M.
Low sensitivity of a whole-blood interferon-gamma release assay for detection of active
tuberculosis.
Clin Infect Dis.
2007;
44
69-73
- 10
Friedman L N, Nash E R, Bryant J. et al .
High rate of negative results of tuberculin and QuantiFERON tests among individuals
with a history of positive skin test results.
Infect Control Hosp Epidemiol.
2006;
27
436-441
- 11
Gray R H, Kigozi G. et al .
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial.
Lancet.
2007;
369
657-666
- 12
Greenwald J L, Burstein G R, Pincus J, Branson B.
A rapid review of rapid HIV antibody tests.
Curr Infect Dis Rep.
2006;
8
125-131
- 13
Grinsztejn B, Nguyen B Y. et al .
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced
patients with multidrug-resistant virus: a phase II randomised controlled trial.
Lancet.
2007;
369
1261-1269
- 14
Hampton T.
Marburg vaccine shows promise: offers postexposure protection in monkeys.
Jama.
2006;
295
2346
- 15
Harper D M. et al .
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against
human papillomavirus types 16 and 18l.
Lancet.
2006;
367
1247-1255
- 16
Hasenoehrl A, Galic T. et al .
In Vitro Activity and In Vivo Efficacy of Icofungipen (PLD-118), a Novel Oral Antifungal
Agent, against the Pathogenic Yeast Candida albicans.
Antimicrob Agents Chemother.
2006;
50
3011-3018
- 17
Hasin T, Davidovitch N, Cohen R. et al .
Postexposure treatment with doxycycline for the prevention of tick-borne relapsing
fever.
N Engl J Med.
2006;
355
148-155
- 18
Hicks C B, Cahn P, Cooper D A. et al .
Durable efficacy of tipranavir-ritonavir in combination with an optimised background
regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients
at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant
patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised
open-label trials.
Lancet.
2006;
368
466-475
- 19
Hill D R, Ford L, Lalloo D G.
Oral cholera vaccines: use in clinical practice.
Lancet Infect Dis.
2006;
6
361-373
- 20
Hoffmann H, Loytved G, Bodmer T.
Interferon-γ-Release-Assays in der Tuberkulosediagnostik.
Internist (Berl).
2007;
48
497-506
- 21
Högenauer C, Hammer F H, Krejs G J, Reisinger E C.
Mechanisms and Management of Antibiotic-Associated Diarrhea.
Clin Infect Dis.
1998;
27
702-710
- 22
Högenauer C, Langner C, Beubler E. et al .
Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis.
N Engl J Med.
2006;
355
2418-2426
- 23
Hornberger J, Robertus K.
Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia
in older adults.
Ann Intern Med.
2006;
145
317-325
- 24
Kabir S.
Cholera vaccines.
Lancet Infect Dis.
2007;
7
176-178
- 25
Klug S J, Hukelmann M, Hollwitz B. et al .
Prevalence of human papillomavirus types in women screened by cytology in Germany.
J Med Virol.
2007;
79
616-525
- 26
Kobashi Y, Obase Y. et al .
Clinical reevaluation of the QuantiFERON TB-2G test as a diagnostic method for differentiating
active tuberculosis from nontuberculous mycobacteriosis.
Clin Infect Dis.
2006;
43
1540-1546
- 27
Krause R, Schwab E, Bachhiesl D, Wenisch C, Krejs G J, Reisinger E C.
Role of Candida in Antibiotic-Associated Diarrhea.
J Infect Dis.
2001;
184
1065-1069
- 28
MacArthur R D.
Darunavir: promising initial results.
Lancet.
2007;
369
1143-1144
- 29
Menzies D, Pai M, Comstock G.
Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas
of uncertainty and recommendations for research.
Ann Intern Med.
2007;
146
340-345
- 30
Munch J, Standker L, Adermann K. et al .
Discovery and Optimization of a Natural HIV-1 Entry Inhibitor Targeting the gp41 Fusion
Peptide.
Cell.
2007;
129
263-275
- 31
Nataro J P, Mai V, Johnson J. et al .
Diarrheagenic Escherichia coli infection in Baltimore, Maryland, and New Haven, Connecticut.
Clin Infect Dis.
2006;
43
402-407
- 32
Oxman M N, Levin M J, Johnson G R. et al .
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
N Engl J Med.
2005;
352
2271-2284
- 33
Pai M, Menzies D.
Interferon-gamma release assays: what is their role in the diagnosis of active tuberculosis?.
Clin Infect Dis.
2007;
44
74-77
- 34
Raad I, Hanna H, Jiang Y. et al .
Comparative Activities of Daptomycin, Linezolid, and Tigecycline against Catheter-Related
Methicillin-Resistant Staphylococcus Bacteremic Isolates Embedded in Biofilm.
Antimicrob Agents Chemother.
2007;
51
1656-1660
- 35 SurvStat. 2007. (Accessed 30.04.2007, 2007, at http://www3.rki.de/SurvStat.)
- 36
Reisinger E C, Burchard G D.
Neues in der Infektiologie und Tropenmedizin.
Dtsch Med Wochenschr.
2006;
131
1474-1478
- 37
RKI .
Zum Welttuberkulosetag 2007. Tuberkulose irgendwo heißt Tuberkulose überall!.
Epidemiol Bul.
2007;
11
87-93
- 38
Rothberg M B, Virapongse A, Smith K J.
Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia
in older adults.
Clin Infect Dis.
2007;
44
1280-1288
- 39
Schmiedeskamp M R, Kockler D R.
Human papillomavirus vaccines.
Ann Pharmacother.
2006;
40
1344-1352
- 40
Seedat J, Zick G, Klare I, Konstabel C, Weiler N, Sahly H.
Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus
faecium infection.
Antimicrob Agents Chemother.
2006;
50
4217-4219
- 41
Sidley P.
South Africa acts to curb spread of lethal strain of TB.
Bmj.
2006;
333
825
- 42
Steiner T S, Samie A, Guerrant R L.
Infectious diarrhea: new pathogens and new challenges in developed and developing
areas.
Clin Infect Dis.
2006;
43
408-410
- 43
STIKO .
Empfehlung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut zur Pertussis-Schutzimpfung.
Epidemiol Bull.
2006;
3
21-23
- 44
STIKO .
Neuerungen in den aktuellen Empfehlungen der Ständigen Impfkommission (STIKO) am RKI
vom Juli 2006.
Epidemiol Bull.
2006;
32
271-276
- 45
STIKO .
Impfung gegen humane Papillomaviren (HPV) für Mädchen von 12 bis 17 Jahren - Empfehlung
und Begründung.
Epidemiol Bull.
2007;
12
97-103
- 46
Taylor D N, Bourgeois A L. et al .
A randomized, double-blind, multicenter study of rifaximin compared with placebo and
with ciprofloxacin in the treatment of travelers’ diarrhea.
Am J Trop Med Hyg.
2006;
74
1060-1066
- 47
Teo J W, Thayalan P, Beer D. et al .
Peptide deformylase inhibitors as potent antimycobacterial agents.
Antimicrob Agents Chemother.
2006;
50
3665-3673
- 48
Tornesello M L. et al .
Prevalence of human papillomavirus genotypes and their variants in high risk West
Africa women immigrants in South Italy.
Infect Agent Cancer.
2007;
2
1
- 49
Treanor J J, Schiff G M. et al .
Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine:
a randomized controlled trial.
Jama.
2007;
297
1577-1582
- 50
Tribble D R, Sanders J W, Pang L W. et al .
Traveler’s diarrhea in Thailand: randomized, double-blind trial comparing single-dose
and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen.
Clin Infect Dis.
2007;
44
338-346
- 51 UNAIDS .Report on the global AIDS epidemic 2006. Geneva: UNAIDS 2006
- 52 WHO .Guidelines for the treatment of severe malaria. (Accessed 2007 - 05 - 11,
2007, at www.who.int/malaria/docs/TreatmentGuidelines2006.pdf ) 2006
- 53
Xu Q A, Yu F, Fan M W. et al .
Immunogenicity and persistence of a targeted anti-caries DNA vaccine.
J Dent Res.
2006;
85
91591-91598
- 54
Xu Q A, Yu F, Fan M W. et al .
Protective efficacy of a targeted anti-caries DNA plasmid against cariogenic bacteria
infections.
Vaccine.
2007;
25
1191-1195
- 55
Stryjewski M E, Chu V H, O’Riordan W D. et al .
Telavancin versus standard therapy for treatment of complicated skin and skin structure
infections caused by gram-positive bacteria: FAST 2 Study.
Antimicrob Agents Chemother.
2006;
50(3)
862-867
- 56
Kohli M, Ferko N, Martin A. et al .
Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine
on the burden of cervical cancer in the UK.
Br J Cancer.
2007;
96(1)
143-150
- 57
Dondorp A, Nosten F, Stepniewska K. et al .
Artesunate versus quinine for treatment of severe falciparum malaria: a randomised
trial.
Lancet.
2005;
366(9487)
717-725
Prof. Dr. med. Emil C. Reisinger
Abteilung für Tropenmedizin und Infektionskrankheiten, Universitätsklinik Rostock
Ernst Heydemann Str. 6
18057 Rostock
Phone: 0381/4947511
Fax: 0381/4947509
Email: emil.reisinger@medizin.uni-rostock.de
